Drug Safety

Research Confirms Safe Use of Marinol for HIV and Cancer Conditions

Published in AIDS Weekly, June 29th, 1998

Unimed Pharmaceuticals, Inc., Chicago, Illinois, announced that San Francisco, California, researchers evaluating clinicians' experiences with Marinol (dronabinol) use have found no observed cases of abuse among patients, confirming its safety in the treatment of appetite loss in people with HIV, and vomiting and nausea in people with cancer.

Study findings were presented by Sarah Calhoun, Haight Ashbury Free Clinics, Inc., San Francisco, California, in conjunction with the College of Problems of Drug Dependency's Annual Scientific Meeting held in Scottsdale, Arizona, during June 1998.

Marinol is the only legally-available synthetic form of THC, the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1998-06-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry